Menü
Das neue sharewise ist da Übersichtlicher, schneller, mit heller und dunkler Ansicht — und allem, was du kennst. Jetzt ausprobieren
You need to sign in or sign up before continuing.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Organon (OGN) Lags Q2 Earnings Estimates
Organon (OGN) Lags Q2 Earnings Estimates

Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago. These figures are

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Organon (OGN) reported revenue of $1.56 billion, down 2.3% over the same period last year. EPS came in at $0.85, compared to $1.00 in the year-ago quarter.

The

Organogenesis Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Organogenesis Q2 Earnings Call Highlights

Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for